Empfehlung
15,7
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
62.9
2 Insider, 62,5M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Stammdaten
Unternehmen
| Name | Lyell Immunopharma, Inc. |
|---|---|
| Ticker | LYEL |
| CIK | 0001806952 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Lyell Immunopharma, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:37:11.52609 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +576,1% | |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +576,1% | |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +576,1% | |
| 2026-03-06 | ARCH Venture Partners IX, LLC | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +576,1% | |
| 2026-03-06 | ARCH Venture Partners IX, LLC | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +576,1% | |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +576,1% | |
| 2026-02-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,455 | 23.39 | -174,372.45 | -8,0% | |
| 2026-02-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,455 | 23.39 | -174,372.45 | -8,0% | |
| 2026-02-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,455 | 23.39 | -174,372.45 | -8,0% | |
| 2026-02-11 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -1,236 | 23.39 | -28,910.04 | -1,3% | |
| 2026-02-11 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -1,671 | 23.39 | -39,084.69 | -1,8% | |
| 2026-02-10 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -109 | 23.12 | -2,520.08 | -0,1% | |
| 2026-02-10 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -147 | 23.12 | -3,398.64 | -0,2% | |
| 2026-02-10 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -254 | 23.12 | -5,872.48 | -0,3% | |
| 2026-02-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -438 | 23.12 | -10,126.56 | -0,5% | |
| 2026-02-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -438 | 23.12 | -10,126.56 | -0,5% | |
| 2026-02-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -438 | 23.12 | -10,126.56 | -0,5% | |
| 2025-12-30 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -936 | 32.32 | -30,251.52 | -1,4% | |
| 2025-12-24 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -1,136 | 38.67 | -43,929.12 | -2,0% | |
| 2025-11-10 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -138 | 16.16 | -2,230.08 | -0,1% | |
| 2025-11-10 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -95 | 16.12 | -1,531.40 | -0,1% | |
| 2025-11-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -412 | 16.11 | -6,637.32 | -0,3% | |
| 2025-11-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -412 | 16.11 | -6,637.32 | -0,3% | |
| 2025-11-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -412 | 16.11 | -6,637.32 | -0,3% | |
| 2025-11-10 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -239 | 16.10 | -3,847.90 | -0,2% | |
| 2025-08-21 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,257 | 10.54 | -76,517.81 | -3,5% | |
| 2025-08-21 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,257 | 10.54 | -76,517.81 | -3,5% | |
| 2025-08-21 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -1,453 | 10.54 | -15,320.43 | -0,7% | |
| 2025-08-12 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -406 | 10.34 | -4,197.23 | -0,2% | |
| 2025-08-12 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -136 | 10.34 | -1,405.97 | -0,1% | |
| 2025-08-12 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -406 | 10.34 | -4,197.23 | -0,2% | |
| 2025-08-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -391 | 10.53 | -4,115.67 | -0,2% | |
| 2025-08-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -391 | 10.53 | -4,115.67 | -0,2% | |
| 2025-08-11 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -131 | 10.53 | -1,378.91 | -0,1% | |
| 2025-03-31 | BRAWLEY OTIS W | Director | Open Market Purchase | 35,640 | 0.56 | 19,958.40 | +0,9% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.